Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Citius Oncology Inc (CTOR)

Citius Oncology Inc (CTOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,399
  • Shares Outstanding, K 88,275
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,760 K
  • EBIT $ -17 M
  • EBITDA $ -24 M
  • 60-Month Beta 3.09
  • Price/Sales 22.72
  • Price/Cash Flow N/A
  • Price/Book 1.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +12.62%
on 01/21/26
1.2600 -7.94%
on 02/12/26
+0.1100 (+10.48%)
since 01/20/26
3-Month
0.9384 +23.61%
on 12/09/25
1.8300 -36.61%
on 12/01/25
+0.0300 (+2.65%)
since 11/20/25
52-Week
0.5506 +110.68%
on 03/17/25
6.1900 -81.26%
on 06/27/25
-0.0400 (-3.33%)
since 02/20/25

Most Recent Stories

More News
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

Third international distribution agreement further advances global access strategy with major markets in Europe

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)

NEW YORK , Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Citius Oncology, Inc. (NASDAQ: CTOR) on behalf of the company's shareholders.  The investigation...

CTOR : 1.1600 (-4.13%)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CRANFORD, N.J. , Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius...

CTOR : 1.1600 (-4.13%)
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

LYMPHIR now available nationwide

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR

CTXR : 0.7090 (+2.60%)
MCK : 947.48 (+1.10%)
CTOR : 1.1600 (-4.13%)

Business Summary

Citius Oncology Inc. platform to develop and commercialize novel targeted oncology therapies. The company is seeking approval from the U.S. Food and Drug Administration of LYMPHIR(TM) for an orphan indication in the treatment of persistent or recurrent cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

See More

Key Turning Points

3rd Resistance Point 1.3000
2nd Resistance Point 1.2600
1st Resistance Point 1.2100
Last Price 1.1600
1st Support Level 1.1200
2nd Support Level 1.0800
3rd Support Level 1.0300

See More

52-Week High 6.1900
Fibonacci 61.8% 4.0357
Fibonacci 50% 3.3703
Fibonacci 38.2% 2.7049
Last Price 1.1600
52-Week Low 0.5506

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar